Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in …
Biotechnology
US, San Carlos [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Vaxcyte, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2020 | - | -5.433 | - | 0.50 | - | -527 | - | 0 | - | 0 | - | 0 |
| 2023 | -3.6900 | -3.423 | 0 | 0 | -239 | -326 | -189 | 0 | -216 | 0 | 39 | 0 |
| 2024 | -4.1400 | -4.260 | 0 | 0 | -402 | -413 | -382 | 0 | -393 | 0 | 50 | 0 |
| 2025 | - | -4.810 | - | 0 | - | -465 | - | 0 | - | 0 | - | 0 |
| 2026 | - | -4.927 | - | 25 | - | 2.F4X/td> | - | 2.F41/td> | - | 2.F41 | - | 2.F41 |
| 2027 | - | -5.342 | - | 42 | - | 1.F5X/td> | - | 1.F51/td> | - | 1.F51 | - | 1.F51 |
| 2028 | - | -3.585 | - | 419 | - | 0.F6X/td> | - | 0.F61/td> | - | 0.F61 | - | 0.F61 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-71.213% $61.35 · MISS
Nov. 6, 2024Price Then
$107.56
Price Target
$147.50
Price Now
$86.15